<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147381</url>
  </required_header>
  <id_info>
    <org_study_id>TaCam 07_MC</org_study_id>
    <secondary_id>DE-02-RG-121/Margreiter</secondary_id>
    <nct_id>NCT00147381</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection</brief_title>
  <official_title>Effectiveness and Safety of Campath-1H as an Induction Agent in Combination With Tacrolimus Monotherapy for Prevention of Graft Rejection Compared to Tacrolimus in Combination With MMF and Steroids in Cadaveric Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Claudia Bösmüller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Campath following Tacrolimus monotherapy is
      more effective in the prevention of renal graft rejection (considering an acute rejection
      rate of 5% for Campath-1H/Tacrolimus and of 22% for Tacrolimus/MMF/Steroids).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major advances in immunosuppressive therapy have resulted in long-term graft survival by the
      use of various drug combinations.However, these combinations carry the risk of e.g.
      infection, malignancy, renal damage, hypertension, diabetes, hyperlipidemia, hirsutism,
      cushingoid facial appearance and bone necrosis.Therefore one of the major goals should be to
      reduce immunosuppression without increasing risk of rejections.

      Based on good results of a pilot study (not a single acute rejection episode during the 18-20
      months observation period despite low level of Tacrolimus and absence of steroids) this
      randomised trial was designed to further evaluate the safety and efficacy of Campath-1H.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy proven acute rejection episodes 6 months after transplantation (Banff Classification)</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biopsy proven acute rejection episodes 12 months after transplantation (Banff Classification)</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 1st biopsy proven acute rejection episode (Banff Cl.)</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who will get antilymphocyte preparation for treatment of steroid resistant acute rejection episodes</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure defined as change from immunosuppressive protocol because of biopsy proven intractable rejection</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (e.g. infections, PTLD)</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Campath-1H 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 20 mg IV infusion over 3-6 hours.
Day 1: Same protocol of Campath-1H and methylprednisolone as on Day 0.
Day 2: No treatment
Day 3: Initial dose of Tacrolimus 0,1 mg/kg/d (0,05 mg/kg/bid)
till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).
Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.
Day 1: No treatment
Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).
till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).
Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Campath-1H 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.
Day 1: No treatment.
Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).
till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).
Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Day 0: Campath-1H 20 mg IV infusion over 3-6 hours
Day 1: Campath-1H 20 mg IV infusion over 3-6 hours</description>
    <arm_group_label>Campath-1H 20 mg</arm_group_label>
    <other_name>MABCAMPATH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.
till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).
Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months.</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Day 0: Campath-1H 30 mg IV infusion over 3-6 hours
Day 1: Campath-1H 30 mg IV infusion over 3-6 hours</description>
    <arm_group_label>Campath-1H 30 mg</arm_group_label>
    <other_name>MABCAMPATH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-65

          -  endstage renal failure with no previous renal transplantation

          -  cadaveric donor

          -  written informed consent

        Exclusion Criteria:

          -  pregnant or nursing women

          -  multi-organ transplant recipients

          -  live donor recipients

          -  re-transplants

          -  panel reactive antibodies (PRA) &gt; 25%

          -  previous treatment with Campath-1H

          -  use of other investigational agents within 6 weeks

          -  active systemic infection

          -  HIV positive patient or donor

          -  positive lymphocyte cytotoxicity cross-match between recipient serum and donor cells

          -  past history of anaphylaxis following exposure to humanized monoclonal antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raimund Margreiter, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University for Surgery and Transplantation, Innsbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G, Firth J, Bradley J, Smith KG, Waldmann H. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 1999 Nov 27;68(10):1613-6.</citation>
    <PMID>10589966</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>June 18, 2012</last_update_submitted>
  <last_update_submitted_qc>June 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University Innsbruck</investigator_affiliation>
    <investigator_full_name>Dr. Claudia Bösmüller</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Campath-1H</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>renal transplantation</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>prevention of acute rejection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

